Focus: Perceptive is a UK-based biotechnology company specializing in medical imaging technologies across neurology, ophthalmology, gastroenterology, and hematology. The company is actively hiring across 35 roles, indicating early-stage growth in a niche imaging diagnostics market.
Profile data last refreshed 7h ago · AI intelligence enriched 3w ago
Growing — net +10 jobs in 30d
29 jobs added vs 19 removed. Steady team buildout.
Perceptive is an early-stage medical imaging biotech with strong R&D hiring momentum but unproven clinical pathway and opaque financials—suited for risk-tolerant scientists seeking equity upside, not stability.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Perceptive
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Perceptive's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Life Sciences Apprenticeship at Perceptive in Hyderabad – Freshers Apply Now - BioTecNika
Life Sciences Apprenticeship at Perceptive in Hyderabad – Freshers Apply Now BioTecNika
Perceptive Discovery and Certis Oncology Announce Strategic Collaboration to Advance Radiopharmaceutical Development - PR Newswire
Perceptive Discovery and Certis Oncology Announce Strategic Collaboration to Advance Radiopharmaceutical Development PR Newswire
Cardio drugmaker Kardigan plans to go public - BioPharma Dive
Cardio drugmaker Kardigan plans to go public BioPharma Dive
Perceptive-affiliated holders report 5.1% stake in Rhythm (RYTM) - Stock Titan
Perceptive-affiliated holders report 5.1% stake in Rhythm (RYTM) Stock Titan
Perceptive (NASDAQ: TRAW) reports 6.1% stake via 979,815 warrants - Stock Titan
Perceptive (NASDAQ: TRAW) reports 6.1% stake via 979,815 warrants Stock Titan
Perceptive group holds 8.28M shares of Amylyx (AMLX) in Schedule 13G/A - Stock Titan
Perceptive group holds 8.28M shares of Amylyx (AMLX) in Schedule 13G/A Stock Titan
Showing 6 of 10 news items
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles